Pulse Biosciences (NASDAQ:PLSE) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Pulse Biosciences (NASDAQ:PLSE) from a sell rating to a hold rating in a report released on Sunday,Wall Street Zen reports.

A number of other analysts also recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Mizuho set a $45.00 price target on shares of Pulse Biosciences in a research report on Monday, August 10th. Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Canaccord Genuity Group increased their price objective on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Finally, Needham & Company LLC initiated coverage on shares of Pulse Biosciences in a research note on Monday, August 17th. They set a “buy” rating and a $58.00 target price for the company. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $45.25.

Pulse Biosciences Stock Performance

Shares of PLSE opened at $53.24 on Friday. The company has a market capitalization of $3.68 billion, a PE ratio of -45.12 and a beta of 1.63. Pulse Biosciences has a 12 month low of $12.56 and a 12 month high of $55.37. The stock’s 50-day moving average price is $37.97 and its two-hundred day moving average price is $28.04.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The company had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. Equities research analysts predict that Pulse Biosciences will post -1.29 EPS for the current fiscal year.

Insider Buying and Selling

In other Pulse Biosciences news, COO Liane Teplitsky purchased 1,001 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were purchased at an average cost of $49.95 per share, with a total value of $49,999.95. Following the completion of the purchase, the chief operating officer owned 4,095 shares in the company, valued at $204,545.25. This represents a 32.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders purchased a total of 4,095 shares of company stock worth $199,931 over the last ninety days. Company insiders own 74.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new position in Pulse Biosciences during the second quarter worth $40,672,000. Bank of America Corp DE acquired a new position in shares of Pulse Biosciences during the second quarter valued at about $40,115,000. California State Teachers Retirement System raised its holdings in shares of Pulse Biosciences by 2,600.0% during the second quarter. California State Teachers Retirement System now owns 567,883 shares of the company’s stock valued at $15,747,000 after purchasing an additional 546,850 shares during the period. State Street Corp boosted its position in shares of Pulse Biosciences by 6.0% during the 4th quarter. State Street Corp now owns 447,067 shares of the company’s stock worth $6,138,000 after purchasing an additional 25,187 shares in the last quarter. Finally, Brooklyn Investment Group boosted its position in shares of Pulse Biosciences by 330.7% during the 4th quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock worth $1,844,000 after purchasing an additional 100,081 shares in the last quarter. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.